Prevention of abdominal adhesion by a polycaprolactone/phospholipid hybrid film containing quercetin and Ag nanoparticles

Nanomedicine ◽  
2021 ◽  
Author(s):  
Reza Hosseinpour-Moghadam ◽  
Shahram Rabbani ◽  
Arash Mahboubi ◽  
Sayyed Abbas Tabatabai ◽  
Azadeh Haeri
Keyword(s):  
Sustained Release ◽  
Histochemical Staining ◽  
In Vivo Studies ◽  
In Vitro Tests ◽  
Potential Candidate ◽  
Control Groups ◽  
Coating Films ◽  
Poly Caprolactone

Aim: To develop quercetin-loaded poly(caprolactone) (PCL)/soybean phosphatidylcholine (PC) films coated with silver (Ag) to prevent the formation of postoperative adhesions (POA). Materials & methods: Films were prepared using the solvent casting method, coated with Ag, and underwent  in vitro tests. In vivo studies were conducted employing an animal model of sidewall defect and cecum abrasion. Results: Films showed sustained release behavior of quercetin and Ag. Coating films with Ag improved their antimicrobial activity. In vivo studies confirmed superior antiadhesion properties of films compared with the control groups evaluated by gross observation, histochemical staining and immunohistochemistry analyses. Conclusion: Ag-Q-PCL-PC films are a potential candidate to prevent POA by acting as a sustained release delivery system and physical barrier.

In vitro and in vivo studies of biaxially electrospun poly(caprolactone)/gelatin nanofibers, reinforced with cellulose nanocrystals, for wound healing applications

Cellulose ◽  
2020 ◽  
Vol 27 (9) ◽  
pp. 5179-5196
Author(s):  
Ahmad Hivechi ◽  
S. Hajir Bahrami ◽  
Ronald A. Siegel ◽  
Peiman B.Milan ◽  
Moein Amoupour
Keyword(s):  
Wound Healing ◽  
Cellulose Nanocrystals ◽  
In Vivo Studies ◽  
Poly Caprolactone

Sustained-release hydrophilic matrix tablets of zileuton: formulation and in vitro/in vivo studies

1997 ◽  
Vol 45 (3) ◽  
pp. 249-256 ◽  
Author(s):  
Yihong Qiu ◽  
Howard Cheskin ◽  
Jackie Briskin ◽  
Kevin Engh
Keyword(s):  
Sustained Release ◽  
Matrix Tablets ◽  
In Vivo Studies ◽  
Hydrophilic Matrix

Analysis of perfluorochemical elimination from the respiratory system

1997 ◽  
Vol 83 (3) ◽  
pp. 1033-1033 ◽  
Author(s):  
Thomas H. Shaffer ◽  
Raymond Foust ◽  
Marla R. Wolfson ◽  
Thomas F. Miller
Keyword(s):  
Respiratory System ◽  
Minute Ventilation ◽  
In Vivo Studies ◽  
In Vitro Tests ◽  
Volume Loss ◽  
Concentration Data ◽  
Expired Gas ◽  
Respiratory Gases

Shaffer, Thomas H., Raymond Foust IIII, Marla R. Wolfson, and Thomas F. Miller, Jr. Analysis of perfluorochemical elimination from the respiratory system. J. Appl. Physiol. 83(3): 1033–1040, 1997.—We describe a simple apparatus for analysis of perfluorochemicals (PFC) in expired gas and thus a means for determining PFC vapor and liquid elimination from the respiratory system. The apparatus and data analysis are based on thermal conduction and mass transfer principles of gases. In vitro studies were conducted with the PFC vapor analyzer to determine calibration curves for output voltage as a function of individual respiratory gases, respiratory gases saturated with PFC vapor, and volume percent standards for percent PFC saturation (%PFC-Sat) in air. Voltage-concentration data for %PFC-Sat of the vapor from the in vitro tests were accurate to within 2.0% from 0 to 100% PFC-Sat, linear ( r = 0.99, P < 0.001), and highly reproducible. Calculated volume loss of PFC liquid over time correlated well with actual loss by weight ( r = 0.99, P < 0.001). In vivo studies with neonatal lambs demonstrated that PFC volume loss and evaporation rates decreased nonlinearly as a function of time. These relationships were modulated by changes in PFC physical properties, minute ventilation, and postural repositioning. The results of this study demonstrate the sensitivity and accuracy of an on-line method for PFC analysis of expired gas and describe how it may be useful in liquid-assisted ventilation procedures for determining PFC volume loss, evaporation rate, and optimum dosing and ventilation strategy.

scholarly journals Antimicrobial Peptides Protect Coho Salmon fromVibrio anguillarum Infections

2000 ◽  
Vol 66 (5) ◽  
pp. 1928-1932 ◽  
Author(s):  
X. Jia ◽  
A. Patrzykat ◽  
R. H. Devlin ◽  
P. A. Ackerman ◽  
G. K. Iwama ◽  
...  
Keyword(s):  
Antimicrobial Peptides ◽  
Coho Salmon ◽  
Vibrio Anguillarum ◽  
Transgenic Fish ◽  
In Vivo Studies ◽  
Bacterial Disease ◽  
Control Groups ◽  
Fish Pathogens

ABSTRACT Fish losses from infectious diseases are a significant problem in aquaculture worldwide. Therefore, we investigated the ability of cationic antimicrobial peptides to protect against infection caused by the fish pathogen Vibrio anguillarum. To identify effective peptides for fish, the MICs of certain antimicrobial peptides against fish pathogens were determined in vitro. Two of the most effective antimicrobial peptides, CEME, a cecropin-melittin hybrid peptide, and pleurocidin amide, a C-terminally amidated form of the natural flounder peptide, were selected for in vivo studies. A single intraperitoneal injection of CEME did not affect mortality rates in juvenile coho salmon infected with V. anguillarum, the causative agent of vibriosis. Therefore, the peptides were delivered continuously using miniosmotic pumps placed in the peritoneal cavity. Twelve days after pump implantation, the fish received intraperitoneal injections ofV. anguillarum at a dose that would kill 50 to 90% of the population. Fish receiving 200 μg of CEME per day survived longer and had significantly lower accumulated mortalities (13%) than the control groups (50 to 58%). Fish receiving pleurocidin amide at 250 μg per day also survived longer and had significantly lower accumulated mortalities (5%) than the control groups (67 to 75%). This clearly shows the potential for antimicrobial peptides to protect fish against infections and indicates that the strategy of overexpressing the peptides in transgenic fish may provide a method of decreasing bacterial disease problems.

scholarly journals Chitosan and Enteric Polymer Based Once Daily Sustained Release Tablets of Aceclofenac: In Vitro and In Vivo Studies

2008 ◽  
Vol 9 (2) ◽  
Author(s):  
Srinivas Mutalik ◽  
Krishnan Manoj ◽  
Meka Sreenivasa Reddy ◽  
Pralhad Kushtagi ◽  
Achutha Nayak Usha ◽  
...  
Keyword(s):  
Sustained Release ◽  
In Vivo Studies ◽  
Once Daily ◽  
Sustained Release Tablets ◽  
Enteric Polymer

In vitro and in vivo Studies of a New Sustained Release Formulation of Morphine

2011 ◽  
Vol 58 (12) ◽  
pp. 647-652
Author(s):  
Amparo Araíco ◽  
Francisca Torres-Molina ◽  
Anas Saadeddin ◽  
Jaime Cárcel-Trullols ◽  
Josefa Alvarez-Fuentes ◽  
...  
Keyword(s):  
Sustained Release ◽  
In Vivo Studies ◽  
Release Formulation ◽  
Sustained Release Formulation

scholarly journals Dental Pulp Stem Cell-Derived Secretome and Its Regenerative Potential

2021 ◽  
Vol 22 (21) ◽  
pp. 12018
Author(s):  
Julia K. Bar ◽  
Anna Lis-Nawara ◽  
Piotr Grzegorz Grelewski
Keyword(s):  
Dental Pulp ◽  
Therapeutic Potential ◽  
Nerve Tissue ◽  
In Vivo Studies ◽  
Deciduous Teeth ◽  
Cartilage Defects ◽  
Potential Candidate ◽  
Paracrine Effect

The therapeutic potential of the dental pulp stem (DSC) cell-derived secretome, consisting of various biomolecules, is undergoing intense research. Despite promising in vitro and in vivo studies, most DSC secretome-based therapies have not been implemented in human medicine because the paracrine effect of the bioactive factors secreted by human dental pulp stem cells (hDPSCs) and human exfoliated deciduous teeth (SHEDs) is not completely understood. In this review, we outline the current data on the hDPSC- and SHED-derived secretome as a potential candidate in the regeneration of bone, cartilage, and nerve tissue. Published reports demonstrate that the dental MSC-derived secretome/conditional medium may be effective in treating neurodegenerative diseases, neural injuries, cartilage defects, and repairing bone by regulating neuroprotective, anti-inflammatory, antiapoptotic, and angiogenic processes through secretome paracrine mechanisms. Dental MSC-secretomes, similarly to the bone marrow MSC-secretome activate molecular and cellular mechanisms, which determine the effectiveness of cell-free therapy. Many reports emphasize that dental MSC-derived secretomes have potential application in tissue-regenerating therapy due to their multidirectional paracrine effect observed in the therapy of many different injured tissues.

scholarly journals Comparative Studies on the Anticoagulant Profile of Branded Enoxaparin and a New Biosimilar Version

2020 ◽  
Vol 26 ◽  
pp. 107602962096082
Author(s):  
Dalia Qneibi ◽  
Eduardo Ramacciotti ◽  
Ariane Scarlatelli Macedo ◽  
Roberto Augusto Caffaro ◽  
Leandro Barile Agati ◽  
...  
Keyword(s):  
Molecular Weight ◽  
High Performance ◽  
Thrombin Generation ◽  
Area Under The Curve ◽  
Factor Xa ◽  
In Vivo Studies ◽  
In Vitro Tests ◽  
Thrombin Time

Low molecular weight heparins (LMWH) represent depolymerized heparin prepared by various methods that exhibit differential, biochemical and pharmacological profiles. Enoxaparin is prepared by benzylation followed by alkaline depolymerization of porcine heparin. Upon the expiration of its patent, several biosimilar versions of enoxaparin have become available. Heparinox (Sodic enoxaparine; Cristália Produtos Químicos Farmacêuticos LTDA, Sao Paulo, Brazil) is a new biosimilar form of enoxaparin. We assessed the molecular weight and the biochemical profile of Heparinox and compared its properties to the original branded enoxaparin (Lovenox; Sanofi, Paris, France). Clotting profiles compared included activated clotting time, activated partial thromboplastin time (aPTT), and thrombin time (TT). Anti-protease assays included anti-factor Xa and anti-factor IIa activities. Thrombin generation was measured using a calibrated automated thrombogram and thrombokinetic profile included peak thrombin, lag time and area under the curve. USP potency was determined using commercially available assay kits. Molecular weight profiling was determined using high performance liquid chromatography. We determined that Heparinox and Lovenox were comparable in their molecular weight profile. Th anticoagulant profile of the branded and biosimilar version were also similar in the clot based aPTT and TT. Similarly, the anti-Xa and anti-IIa activities were comparable in the products. No differences were noted in the thrombin generation inhibitory profile of the branded and biosimilar versions of enoxaparin. Our studies suggest that Heparinox is bioequivalent to the original branded enoxaparin based upon in vitro tests however will require further in vivo studies in animal models and humans to determine their clinical bioequivalence.

Formulation of sustained-release microspheres of cefixime with enhanced oral bioavailability and antibacterial potential

2019 ◽  
Vol 10 (12) ◽  
pp. 769-782
Author(s):  
Karan Razdan ◽  
Nikhil S Sahajpal ◽  
Kuldeep Singh ◽  
Harmanpreet Singh ◽  
Harjeet Singh ◽  
...  
Keyword(s):  
Sustained Release ◽  
Entrapment Efficiency ◽  
Salmonella Typhi ◽  
In Vivo Studies ◽  
In Vitro Drug Release ◽  
Dosing Frequency ◽  
Twofold Decrease ◽  
Antibacterial Potential

Aim: The present work focused on the development of sustained-release microsphere formulation of cefixime to provide reduction in dosing frequency, improved antibacterial activity and patient compliance. Methodology & results: Microspheres were prepared by modified emulsion solvent evaporation method and evaluated by in vitro and in vivo studies. Optimized formulation (FK-07) was found to have entrapment efficiency of 81.12 ± 0.93% and particle size of 166.82 ± 0.86 μm. FK-07 sustained release up to 24 h as demonstrated by in vitro drug release and in vivo pharmacokinetic study in rats. FK-07 showed approximately twofold increase in bioavailability and twofold decrease in MIC90 value against Escherichia coli, Klebsiella pneumoniae and Salmonella typhi in comparison to marketed formulation. Conclusion: Sustaining the release of cefixime using microspheres enhanced its bioavailability, antibacterial efficacy and will help in reducing its dosing frequency.

Sign in / Sign up

Export Citation Format

Share Document